Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 14.3% during trading on Friday . The stock traded as high as C$0.40 and last traded at C$0.40. 813,546 shares were traded during mid-day trading, an increase of 19% from the average session volume of 681,348 shares. The stock had previously closed at C$0.35.
Hemostemix Stock Performance
The firm has a market cap of C$33.98 million, a price-to-earnings ratio of -19.50 and a beta of 0.20. The business’s 50-day moving average is C$0.12 and its 200-day moving average is C$0.09.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- What does consumer price index measure?
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Buy-and-Hold Stocks for Long-Term Growth
- What is MarketRank™? How to Use it
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
